Best Investments for
ACRO Biomedical plans a reverse takeover to place its assets into a Hong Kong holding company
Lilly's chairman and CEO David Ricks said in an earnings call that he was confident in the risk-benefit profile for both proposed doses of the new drug.
Doubleline's Gundlach Launches Facebook Short Campaign, Greenlight's Einhorn believes Assured Guarantee has massive losses "baked in" while Bill Ackman Protégé Scott Ferguson eyes a break up of Britain's WhitBread plc.
Jim Cramer and our other experts discus China and tariffs, the 10 year nearing 3%, technical analysis, and biotech stocks.
Akorn shares plummeted Monday after Germany's Fresenius Medical ditched its planned $5 billion takeover amid allegations of data misconduct at the Lake Forest, Ill.-based generic drugmaker.
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Biotech ETF , we found that the implied analyst target price for the ETF based upon its underlying holdings is $128.36 per unit.
Hong Kong exchange to reveal conclusions on Tuesday of public consultation on what could lead to biggest listing reforms in 30 years
No federal legality, no problem. These cannabis firms are using the complicated regulatory landscape to win business and churn profits.
Jim Cramer and our other experts discuss who will be the first trillion dollar company, chip stocks, and market complacency.
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares where we have detected an approximate $81.4 million dollar outflow -- that's a 13.5% decrease week over week (from 7,061,600 to 6,111,600). START SLIDESHOW:Click here to find out which 9 other ETFs experienced notable outflows » The chart below shows the one year price performance of LABU, versus its 200 day moving average: Looking at the chart above, LABU's low point in its 52 week range is $41.40 per share, with $116.54 as the 52 week high point — that compares with a last trade of $84.50.
How do you get a stock moving? Jim Cramer says the answer is to invest in technology.
Dan Browne, co-founder, president and CEO of Revance Therapeutics, tells Jim Cramer his company is developing an alternative to Botox.
The list of reasons for my short-term bearishness keeps growing.
In trading on Wednesday, shares of Adamas Pharmaceuticals Inc crossed above their 200 day moving average of $25.72, changing hands as high as $26.26 per share. Adamas Pharmaceuticals Inc shares are currently trading up about 3.4% on the day.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.